Shares of Merck (MRK) and Moderna (MRNA) spiked in the premarket on Wednesday after the companies said that their jointly developed messenger RNA-based cancer therapy, intismeran autogene, succeeded in a late-stage trial for patients with melanoma, a type of skin cancer. The Phase 3 INTerpath-001 trial was designed to evaluate intismeran in combination with Merck's (MRK) blockbuster anti-PD-1 therapy Keytruda in more than 1,100 patients with stage IIB-IV melanoma whose cancer has been completely resected. According to its topline data, INTerpath-001 met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival, marking the first late-stage...